Repositioning Candidate Details
| Candidate ID: | R0759 |
| Source ID: | DB05282 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MCC |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Bladder cancer |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MCC has a therapeutic potential in high grade transitional cell carcinomas of the bladder, including refractory CIS. The combination of MCC with hyaluronic acid (HA) enhances both the apoptosis-inducing activity of MCC against prostate cancer cell lines, and the immune stimulatory activity of MCC (stimulation of anticancer cytokine synthesis by human immune effector cells). |
| Targets: | Apoptosis-inducing factor 1, mitochondrial |
| Inclusion Criteria: | Therapeutic strategy associated |
